Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Nasopharyngeal Carcinoma 3Glioblastoma 3Cytomegalovirus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Neoplasm Metastasis 1Multiple Acyl Coenzyme A Dehydrogenase Deficiency 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Herpes Simplex 1Head and Neck Neoplasms 1HIV Infections 1Fatigue Syndrome, Chronic 1Fatigue 1EBV Lymphomas 1

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × Valganciclovir × Clear all
NCT06302140 2025-01-20

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Viracta Therapeutics, Inc.

Phase 1 Terminated
8 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡